Conversely, combining the STING agonist with a COX‐2 inhibitor led to a significant reduction in tumor volume and improved survival in a mouse model of colon cancer.[42c] The survival of the mice was further extended when an anti‐PD‐1 antibody was added to the combination. Here, PTGS2 is linked to malignant colon neoplasm.